The present invention relates generally to implantable metallic medical devices. More specifically, the present invention relates to implantable medical devices, including, for example, surgical and endoluminal vascular grafts, stent grafts, skin grafts, shunts, bone grafts, surgical patches, non-vascular conduits, valvular leaflets, filters, occlusion membranes, sphincters, artificial tendons and ligaments. More specifically, the present invention relates to implantable medical grafts fabricated of metallic or pseudometallic films of biocompatible materials having a plurality of microperforations passing through the film. The plurality of microperforations may serve multiple purposes, including, for example, permitting geometric deformation of the film, imparting a fabric-like quality to the film, and imparting flexibility to the film. The term “fabric-like” is intended to mean a quality of being pliable and/or compliant in a manner similar to that found with natural or synthetic woven fabrics.
The inventive implantable grafts are fabricated entirely of self-supporting films made of biocompatible metals or biocompatible pseudometals. Heretofore in the field of implantable medical devices, it is unknown to fabricate an implantable medical device that comprises a graft at least as one of its elements, such as a stent graft, entirely of self-supporting metal or pseudometal materials. As used herein the term “graft” is intended to indicate any type of device or part of a device that comprises essentially a material delimited by two surfaces where the distance between said surfaces is the thickness of the graft and that exhibits integral dimensional strength and that has microperforations that pass through the thickness of the graft. The inventive grafts may be formed in planar sheets, toroids, and in other shapes as particular applications may warrant. However, for purposes of illustration only, the present application will refer to tubular grafts. For purposes of this application, the terms “pseudometal” and “pseudometallic” are intended to mean a biocompatible material which exhibits biological response and material characteristics substantially the same as biocompatible metals. Examples of pseudometallic materials include, for example, composite materials and ceramics. Composite materials are composed of a matrix material reinforced with any of a variety of fibers made from ceramics, metals, carbon, or polymers.
When implanted into the body, metals are generally considered to have superior biocompatibility than that exhibited by polymers used to fabricate commercially available polymeric grafts. It has been found that when prosthetic materials are implanted, integrin receptors on cell surfaces interact with the prosthetic surface. The integrin receptors are specific for certain ligands in vivo. If a specific protein is adsorbed on a prosthetic surface and the ligand exposed, cellular binding to the prosthetic surface may occur by integrin-ligand docking. It has also been observed that proteins bind to metals in a more permanent fashion than they do to polymers, thereby providing a more stable adhesive surface. The conformation of proteins coupled to surfaces of most medical metals and alloys appears to expose greater numbers of ligands and preferentially attract endothelial cells having surface integrin clusters to the metal or alloy surface relative to leukocytes. Finally, metals and metal alloys exhibit greater resistance to degradation of metals relative to polymers, thereby providing greater long-term structural integrity and stable interface conditions.
Because of their relatively greater adhesive surface profiles, metals are also susceptible to short-term platelet activity and/or thrombogenicity. These deleterious properties may be offset by administration of pharmacologically active antithrombogenic agents in routine use today. Surface thrombogenicity usually disappears 1-3 weeks after initial exposure. Antithrombotic coverage is routinely provided during this period of time for coronary stenting. In non-vascular applications such as musculoskeletal and dental, metals have also greater tissue compatibility than polymers because of similar molecular considerations. The best article to demonstrate the fact that all polymers are inferior to metals is van der Giessen, W J. et al. Marked inflammatory sequelae to implantation of biodegradable and non-biodegradable polymers in porcine coronary arteries, Circulation, 1996:94(7):1690-7.
Normally, endothelial cells (EC) migrate and proliferate to cover denuded areas until confluence is achieved. Migration, quantitatively more important than proliferation, proceeds under normal blood flow roughly at a rate of 25 μm/hr or 2.5 times the diameter of an EC, which is nominally 10 μm. EC migrate by a rolling motion of the cell membrane, coordinated by a complex system of intracellular filaments attached to clusters of cell membrane integrin receptors, specifically focal contact points. The integrins within the focal contact sites are expressed according to complex signaling mechanisms and eventually couple to specific amino acid sequences in substrate adhesion molecules. An EC has roughly 16-22% of its cell surface represented by integrin clusters. Davies, P. F., Robotewskyi A., Griem M. L. Endothelial cell adhesion in real time. J. Clin. Invest. 1993; 91:2640-2652, Davies, P. F., Robotewski, A., Griem, M. L., Qualitative studies of endothelial cell adhesion, J. Clin. Invest. 1994; 93:2031-2038. This is a dynamic process, which implies more than 50% remodeling in 30 minutes. The focal adhesion contacts vary in size and distribution, but 80% of them measure less than 6 μm2, with the majority of them being about 1 μm2, and tend to elongate in the direction of flow and concentrate at leading edges of the cell. Although the process of recognition and signaling to determine specific attachment receptor response to attachment sites is incompletely understood, availability of attachment sites will favorably influence attachment and migration. It is known that materials commonly used as medical grafts, such as polymers, do not become covered with EC and therefore do not heal after they are placed in the arteries. It is therefore an object of this invention to replace polymer grafts with metal grafts that can potentially become covered with EC and can heal completely. Furthermore, heterogeneities of materials in contact with blood flow are preferably controlled by using vacuum deposited materials.
There have been numerous attempts to increase endothelialization of implanted medical devices such as stents, including covering the stent with a polymeric material (U.S. Pat. No. 5,897,911), imparting a diamond-like carbon coating onto the stent (U.S. Pat. No. 5,725,573), covalently binding hydrophobic moieties to a heparin molecule (U.S. Pat. No. 5,955,588), coating a stent with a layer of blue to black zirconium oxide or zirconium nitride (U.S. Pat. No. 5,649,951), coating a stent with a layer of turbostratic carbon (U.S. Pat. No. 5,387,247), coating the tissue-contacting surface of a stent with a thin layer of a Group VB metal (U.S. Pat. No. 5,607,463), imparting a porous coating of titanium or of a titanium alloy, such as Ti—Nb—Zr alloy, onto the surface of a stent (U.S. Pat. No. 5,690,670), coating the stent, under ultrasonic conditions, with a synthetic or biological, active or inactive agent, such as heparin, endothelium derived growth factor, vascular growth factors, silicone, polyurethane, or polytetrafluoroethylene, U.S. Pat. No. 5,891,507), coating a stent with a silane compound with vinyl functionality, then forming a graft polymer by polymerization with the vinyl groups of the silane compound (U.S. Pat. No. 5,782,908), grafting monomers, oligomers or polymers onto the surface of a stent using infrared radiation, microwave radiation or high voltage polymerization to impart the property of the monomer, oligomer or polymer to the stent (U.S. Pat. No. 5,932,299). However, all these approaches do not address the lack of endothelialization of polymer grafts.
It is, therefore, desirable to fabricate the inventive graft of metallic and/or pseudometallic materials. The inventive metal devices may be fabricated of pre-existing conventional wrought metallic materials, such as stainless steel or nitinol hypotubes, or may be fabricated by thin film vacuum deposition techniques. In accordance with the present invention, it is preferable to fabricate the inventive implantable devices by vacuum deposition. Vacuum deposition permits greater control over many material characteristics and properties of the resulting formed device. For example, vacuum deposition permits control over grain size, grain phase, grain material composition, bulk material composition, surface topography, mechanical properties, such as transition temperatures in the case of a shape memory alloy. Moreover, vacuum deposition processes will permit creation of devices with greater material purity without the introduction of large quantities of contaminants that adversely affect the material, mechanical or biological properties of the implanted device. Vacuum deposition techniques also lend themselves to fabrication of more complex devices than those susceptible of manufacture by conventional cold-working techniques. For example, multi-layer structures, complex geometrical configurations, extremely fine control over material tolerances, such as thickness or surface uniformity, are all advantages of vacuum deposition processing.
In vacuum deposition technologies, materials are formed directly in the desired geometry, e.g., planar, tubular, etc. The common principle of vacuum deposition processes is to take a material in a minimally processed form, such as pellets or thick foils, known as the source material and atomize them. Atomization may be carried out using heat, as is the case in physical vapor deposition, or using the effect of collisional processes, as in the case of sputter deposition, for example. In some forms of deposition, a process, such as laser ablation, which creates microparticles that typically consist of one or more atoms, may replace atomization; the number of atoms per particle may be in the thousands or more. The atoms or particles of the source material are then deposited on a substrate or mandrel to directly form the desired object. In other deposition methodologies, chemical reactions between ambient gases introduced into the vacuum chamber, i.e., the gas source, and the deposited atoms and/or particles are part of the deposition process. The deposited material includes compound species that are formed due to the reaction of the solid source and the gas source, such as in the case of chemical vapor deposition. In most cases, the deposited material is then either partially or completely removed from the substrate, to form the desired product.
A first advantage of vacuum deposition processing is that vacuum deposition of the metallic and/or pseudometallic films permits tight process control and films may be deposited that have regular, homogeneous atomic and molecular pattern of distribution along their fluid-contacting surfaces. This avoids the marked variations in surface composition, creating predictable oxidation and organic adsorption patterns and has predictable interactions with water, electrolytes, proteins and cells. Particularly, EC migration is supported by a homogeneous distribution of binding domains that serve as natural or implanted cell attachment sites, in order to promote unimpeded migration and attachment.
Secondly, in addition to materials and devices that are made of a single metal or metal alloy, henceforth termed a layer, the inventive grafts may be comprised of a layer of biocompatible material or of a plurality of layers of biocompatible materials formed upon one another into a self-supporting multilayer structure because multilayer structures are generally known to increase the mechanical strength of sheet materials, or to provide special qualities by including layers that have special properties such as superelasticity, shape memory, radio-opacity, corrosion resistance etc. A special advantage of vacuum deposition technologies is that it is possible to deposit layered materials and thus films possessing exceptional qualities may be produced (cf., H. Holleck, V. Schier: Multilayer PVD coatings for wear protection, Surface and Coatings Technology, Vol. 76-77 (1995) pp. 328-336). Layered materials, such as superstructures or multilayers, are commonly deposited to take advantage of some chemical, electronic, or optical property of the material as a coating; a common example is an antireflective coating on an optical lens. Multilayers are also used in the field of thin film fabrication to increase the mechanical properties of the thin film, specifically hardness and toughness.
Thirdly, the design possibilities for possible configurations and applications of the inventive graft are greatly enhanced by employing vacuum deposition technologies. Specifically, vacuum deposition is an additive technique that lends itself toward fabrication of substantially uniformly thin materials with potentially complex three dimensional geometries and structures that cannot be cost-effectively achieved, or in some cases achieved at all, by employing conventional wrought fabrication techniques. Conventional wrought metal fabrication techniques may entail smelting, hot working, cold working, heat treatment, high temperature annealing, precipitation annealing, grinding, ablation, wet etching, dry etching, cutting and welding. All of these processing steps have disadvantages including contamination, material property degradation, ultimate achievable configurations, dimensions and tolerances, biocompatibility and cost. For example conventional wrought processes are not suitable for fabricating tubes having diameters greater than about 20 mm diameter, nor are such processes suitable for fabricating materials having wall thicknesses down to about 5 μm with sub-μm tolerances.
While the inventive self-supporting metal or pseudometal graft may be fabricated of conventionally fabricated wrought materials, in accordance with the best mode contemplated for the present invention, the inventive graft is preferably fabricated by vacuum deposition techniques. By vacuum depositing the metal and/or pseudometallic film as the precursor material for the inventive graft, it is possible to more stringently control the material, biocompatibility and mechanical properties of the resulting film material and graft than is possible with conventionally fabricated graft-forming materials. The inventive self-supporting graft may be used alone, i.e., the whole implantable device may be made of a single graft, or it may be a part of a structure where the graft is used in conjunction either with other grafts, or in conjunction with other structural elements, such as scaffolds, stents, and other devices. The term “in conjunction” may mean actual connection, such as that made by welding, fusing, or other joining methods, as well as being made from the same piece of material by forming some area of the piece into a graft and some other area of the piece into another member or part of the device.
In accordance with a preferred embodiment of the invention, there is provided a self-supporting graft member having a plurality of microperforations passing through the wall thickness of the graft. The graft member may assume virtually any geometric configuration, including sheets, tubes or rings. The plurality of microperforations may serve to impart geometric compliance to the graft, geometric distendability to the graft and/or limit or permit the passage of body fluids or biological matter through the graft, such as facilitating transmural endothelialization while preventing fluid flow through the wall of the graft under normal physiological conditions. The plurality of microperforations may also impart a fabric-like quality to the graft by imparting pliability and/or elastic, plastic or superelastic compliance to the graft, such as that required for longitudinal flexibility in the case of a vascular graft.
In a first embodiment, the graft may be made from plastically deformable materials such that upon application of a force, the microperforations geometrically deform to impart permanent enlargement of one or more axes of the graft, such as length in the case of a planar graft, e.g., a surgical patch graft, or diameter, such as in the case of a tubular graft, e.g., a vascular graft. In a second embodiment, the graft may be fabricated of elastic or superelastic materials. Elastic and/or superelastic materials will permit the microperforations to geometrically deform under an applied force in a manner that allows for a recoverable change in one or more axes of the graft.
In each of the first and second embodiments of the invention, the graft may be fabricated in such a manner as to have fabric-like qualities by controlling the film thickness, material properties and geometry of the plurality of microperforations. Furthermore, in such cases where minimally invasive delivery is required, such as for endoluminal delivery of vascular grafts, the first and second embodiments allow for delivery using balloon expansion and self-expansion, respectively, or a combination of both. Minimally invasive delivery may also be accomplished by folding the graft for delivery similar to the manner in which an angioplasty balloon is creased and fluted or folded. The graft may be delivered by unfolding the device in vivo either by assistance such as by using a balloon, or by the graft material's plastic, elastic or superelastic properties or by a combination thereof. After delivery, the plurality of microperforations may be patterned in such a manner as to allow for additional dimensional enlargement of the graft member by elastic or plastic deformation such as a radially expansive positive pressure.
For some applications it is preferable that the size of each of the plurality of microperforations be such as to permit cellular migration through each opening, without permitting fluid flow there through. In this manner, for example, blood cannot flow through the plurality of microperforations (in their deformed or un-deformed state), but various cells or proteins may freely pass through the plurality of microperforations to promote graft healing in vivo. For other applications, moderate amounts of fluid flow through the plurality of deformed or un-deformed microperforations may be acceptable. For example, endoluminal saphenous vein grafts may be fabricated with microperforations that serve the dual function of permitting transmural endothelialization while also excluding biological debris, such as thrombus from passing through the wall thickness of the graft, effectively excluding detrimental matter from entering the circulation. In this example, each of the plurality of microperforations in either their deformed or undeformed state, may exceed several hundred microns.
Those skilled in the art will understand that a direct relationship exists between the size of pores and the overall ratio of expansion or deformability of an implantable graft. Generally, therefore, it is appreciated that pore sizes must increase in order to increase the effective attainable degree of expansion or deformation of the graft.
For applications where large deformation and small pore size are both requirements, in accordance with another aspect of the inventive graft embodiment, it is contemplated that two or more graft members are employed such as diametrically concentric grafts for tubular configurations. The two or more graft members have a pattern of a plurality of microperforations passing there through, with the plurality of patterned microperforations being positioned out of phase relative to one another such as to create a tortuous cellular migration pathway through the wall of the concentrically engaged first and second graft members as well as a smaller effective pore size. In order to facilitate cellular migration through and healing of the first and second graft members in vivo, it may be preferable to provide additional cellular migration pathways that communicate between the plurality of microperforations in the first and second graft members. These additional cellular migration pathways, if necessary, may be imparted as 1) a plurality of projections formed on either the luminal surface of the second graft or the abluminal surface of the first graft, or both, which serve as spacers and act to maintain an annular opening between the first and second graft members that permits cellular migration and cellular communication between the plurality of microperforations in the first and second graft members, 2) a plurality of microgrooves, which may be random, radial, helical, or longitudinal relative to the longitudinal axis of the first and second graft members, the plurality of microgrooves being of a sufficient size to permit cellular migration and propagation along the groove, the microgrooves serve as cellular migration conduits between the plurality of microperforations in the first and second graft members, or 3) where the microperforations cause out of plane motion of the graft material upon deformation thereby keeping a well defined space between the planes originally defining the facing surfaces of the grafts.
The graft member or members may be formed as a monolayer film, or may be formed from a plurality of film layers formed one upon another. The particular material used to form each layer of biocompatible metal and/or pseudometal is chosen for its biocompatibility, corrosion-fatigue resistance and mechanical properties, i.e., tensile strength, yield strength. The metals include, without limitation, the following: titanium, vanadium, aluminum, nickel, tantalum, zirconium, chromium, silver, gold, silicon, magnesium, niobium, scandium, platinum, cobalt, palladium, manganese, molybdenum and alloys thereof, such as zirconium-titanium-tantalum alloys, nitinol, and stainless steel. Additionally, each layer of material used to form the graft may be doped with another material for purposes of improving properties of the material, such as radiopacity or radioactivity, by doping with tantalum, gold, or radioactive isotopes.
With the foregoing as background, we turn now to a description of the present invention with reference the preferred embodiments thereof and with reference to the accompanying figures. As noted above, the inventive microporous metallic implantable devices may assume a wide number of geometric configurations, including, for example, planar sheets, tubes or toroids. For ease of reference, however, the accompanying figures and the following description of the invention will refer to tubular implantable graft members. Those skilled in the art, however, will understand that this is merely an exemplary geometric configuration and is not intended to limit the scope of the invention to tubular members or be limited in application to graft members.
With particular reference to
In accordance with a preferred embodiment of the present invention, the plurality of microperforations 20 is patterned in such a manner as to define deformation regions of the body member 12. The thickness 18 is between 0.1 μm and 75 μm, preferably between 1 μm and 50 μm. When fabricated within these thickness ranges, the graft 10 has a thickness 18 which is thinner than the wall thickness of conventional non-metallic implantable grafts and that of conventional metal endoluminal stents.
The plurality of microperforations is patterned in a regular array forming a regular array of microperforations 20 in both the longitudinal and circumferential axes of the body member 12. For purposes of reference, the pattern of microperforations 20 will, hereinafter, be described with reference to a planar X-Y axes, which in a tubular member will correspond to the longitudinal or circumferential axes of the tubular member. Those of ordinary skill in the art will understand that reference to X-axis or Y-axis when applied to a tubular member may be used such that the X-axis may correspond to either the longitudinal axis of circumferential direction of the tubular member and the Y-axis may also be translated to the corresponding circumferential direction or longitudinal axis or the tubular member.
It will be appreciated by those of ordinary skill in the art that individual different geometric patterns may have associated intended uses, function or mechanical requirements of a particular device. Thus, the particular intended use of the implantable member 12 will be a consideration in the selection of the particular geometric pattern for the plurality of microperforations 20. For example, where the implantable member 12 has an intended use as a free-standing implantable endoluminal vascular graft, a large circumferential expansion ratio, significant hoop strength and longitudinal flexibility may be desirable. Thus, a particular geometry of the plurality of microperforations 20 that offers these properties will be selected. The plurality of microperforations 20 also affects the material properties of the implantable member 10. For example, the geometry each microperforation 20 may be altered so that each microperforation 20 exhibits stress-strain relief capabilities or the microperforations 20 may control whether geometric deformation of the microperforations 20 are plastic, elastic or superelastic deformation. Thus, both the geometry of the individual microperforations 20, the orientation of the microperforations 20 relative to the X-Y axis of the implantable member 10 and the pattern of the microperforations 20 may be selected to directly impart, affect or control the mechanical and material properties of the implantable member 10.
Different geometric patterns for the plurality of microperforations 20 in accordance with the preferred embodiments of the invention are illustrated in
The first geometry 30 of the plurality of microperforations 32a, 32b illustrated in
In each of
In accordance with a fourth geometry of the plurality of microperforations 20 illustrated in
Those skilled in the art will understand that each of the microperforations 20 are capable of undergoing deformation upon application of a sufficient force. In a tubular geometry, the graft 12 may deform both circumferentially and longitudinally. As is illustrated in
As depicted in
Thus, one embodiment of the present invention provides a new metallic and/or pseudometallic implantable graft that is biocompatible, geometrically changeable either by folding and unfolding or by application of a plastically, elastically or superelastically deforming force, and capable of endoluminal delivery with a suitably small delivery profile. Suitable metal materials to fabricate the inventive graft are chosen for their biocompatibility, mechanical properties, i.e., tensile strength, yield strength, and their ease of fabrication. The compliant nature of the inventive graft material may be employed to form the graft into complex shapes by deforming the inventive graft over a mandrel or fixture of the appropriate design. Plastic deformation and shape setting heat treatments may be employed to ensure the inventive implantable members 10 retain a desired conformation.
According to a first preferred method of making the graft of the present invention, the graft is fabricated of vacuum deposited metallic and/or pseudometallic films. With particular reference to
Thus, the present invention provides a new metallic and/or pseudometallic implantable graft that is biocompatible, compliant, and geometrically changeable either by folding and unfolding or by application of a plastically, elastically or superelastically deforming force, and, in some cases, capable of endoluminal delivery with a suitably small delivery profile and suitably low post-delivery profile. Suitable metal materials to fabricate the inventive graft are chosen for their biocompatibility, mechanical properties, i.e., tensile strength, yield strength, and in the case where vapor deposition is deployed, their ease of deposition include, without limitation, the following: titanium, vanadium, aluminum, nickel, tantalum, zirconium, chromium, silver, gold, silicon, magnesium, niobium, scandium, platinum, cobalt, palladium, manganese, molybdenum and alloys thereof, such as zirconium-titanium-tantalum alloys, nitinol, and stainless steel. Examples of pseudometallic materials potentially useful with the present invention include, for example, composite materials and ceramics.
The present invention also provides a method of making the inventive expandable metallic graft by vacuum deposition of a graft-forming metal or pseudometal and formation of the microperforations either by removing sections of deposited material, such as by etching, EDM, ablation, or other similar methods, or by interposing a pattern mask, corresponding to the microperforations, between the target and the source during deposition processing. Alternatively, a pre-existing metal and/or pseudometallic film manufactured by conventional non-vacuum deposition methodologies, such as wrought hypotube or sheet, may be obtained, and the microperforations formed in the pre-existing metal and/or pseudometallic film by removing sections of the film, such as by etching, EDM, ablation, or other similar methods. An advantage of employing multilayer film structures to form the inventive graft is that differential functionalities may be imparted in the discrete layers. For example, a radiopaque material such as tantalum may form one layer of a structure while other layers are chosen to provide the graft with its desired mechanical and structural properties.
In accordance with the preferred embodiment of fabricating the inventive microporous metallic implantable device in which the device is fabricated from vacuum deposited nitinol tube, a cylindrical deoxygenated copper substrate is provided. The substrate is mechanically and/or electropolished to provide a substantially uniform surface topography for accommodating metal deposition thereupon. A cylindrical hollow cathode magnetron sputtering deposition device was employed, in which the cathode was on the outside and the substrate was positioned along the longitudinal axis of the cathode. A cylindrical target consisting either of a nickel-titanium alloy having an atomic ratio of nickel to titanium of about 50-50% and which can be adjusted by spot welding nickel or titanium wires to the target, or a nickel cylinder having a plurality of titanium strips spot welded to the inner surface of the nickel cylinder, or a titanium cylinder having a plurality of nickel strips spot welded to the inner surface of the titanium cylinder is provided. It is known in the sputter deposition arts to cool a target within the deposition chamber by maintaining a thermal contact between the target and a cooling jacket within the cathode. In accordance with the present invention, it has been found useful to reduce the thermal cooling by thermally insulating the target from the cooling jacket within the cathode while still providing electrical contact to it. By insulating the target from the cooling jacket, the target is allowed to become hot within the reaction chamber. Two methods of thermally isolating the cylindrical target from the cooling jacket of the cathode were employed. First, a plurality of wires having a diameter of 0.0381 mm were spot welded around the outer circumference of the target to provide an equivalent spacing between the target and the cathode cooling jacket. Second, a tubular ceramic insulating sleeve was interposed between the outer circumference of the target and the cathode cooling jacket. Further, because the Ni—Ti sputtering yields can be dependant on target temperature, methods which allow the target to become uniformly hot are preferred.
The deposition chamber was evacuated to a pressure less than or about 2-5×10−7 Torr and pre-cleaning of the substrate is conducted under vacuum. During the deposition, substrate temperature is preferably maintained within the range of 300 and 700 degrees Centigrade. It is preferable to apply a negative bias voltage between 0 and −1000 volts to the substrate, and preferably between −50 and −150 volts, which is sufficient to cause energetic species arriving at the surface of the substrate. During deposition, the gas pressure is maintained between 0.1 and 40 mTorr but preferably between 1 and 20 mTorr. Sputtering preferably occurs in the presence of an Argon atmosphere. The argon gas must be of high purity and special pumps may be employed to reduce oxygen partial pressure. Deposition times will vary depending upon the desired thickness of the deposited tubular film. After deposition, the plurality of microperforations are formed in the tube by removing regions of the deposited film by etching, such as chemical etching, ablation, such as by excimer laser or by electric discharge machining (EDM), or the like. After the plurality of microperforations are formed, the formed microporous film is removed from the copper substrate by exposing the substrate and film to a nitric acid bath for a period of time sufficient to remove dissolve the copper substrate.
A 5 μm thick NiTi graft having a pattern of microperforations consisting of parallel staggered longitudinally oriented linear slots, each slot being 430 μm length, 25 μm width, and having 50 μm diameter fillets on each end of each linear slot, was mounted onto a 6 mm NiTi stent and delivered endoluminally to the left carotid artery of a swine. After 28 days, the swine was euthanized, and the graft explanted from the left carotid artery. Samples were prepared using standard hematoxylin and eosin staining procedures, and microscope slides prepared. As illustrated in
While the present invention has been described with reference to its preferred embodiments, those of ordinary skill in the art will understand and appreciate that variations in materials, dimensions, geometries, and fabrication methods may be or become known in the art, yet still remain within the scope of the present invention which is limited only by the claims appended hereto.
The present application is a divisional of application Ser. No. 11/157,139, filed Jun. 20, 2005 that issued as U.S. Pat. No. 7,641,682 on Jan. 5, 2010, which is continuation of application Ser. No. 10/135,626, filed Apr. 29, 2002 that issued as U.S. Pat. No. 6,936,066 on Aug. 10, 2005, which corresponds to and claims priority to provisional patent application U.S. Ser. No. 60/302,797, filed Jul. 3, 2001; Ser. No. 09/443,929, filed Nov. 19, 1999 that issued as U.S. Pat. No. 6,379,383 on Apr. 30, 2002; and 09/532,164 filed Mar. 20, 2000 that issued as U.S. Pat. No. 6,537,310 on Mar. 25, 2003.
Number | Name | Date | Kind |
---|---|---|---|
3197788 | Segger | Aug 1965 | A |
4510182 | Cornils et al. | Apr 1985 | A |
4751099 | Niino et al. | Jun 1988 | A |
4846834 | von Recum et al. | Jul 1989 | A |
5049251 | Inoue | Sep 1991 | A |
5061914 | Busch et al. | Oct 1991 | A |
5084151 | Vallana | Jan 1992 | A |
5133845 | Vallana et al. | Jul 1992 | A |
5242710 | Claar et al. | Sep 1993 | A |
5277933 | Claar et al. | Jan 1994 | A |
5370684 | Vallana et al. | Dec 1994 | A |
5387247 | Vallana et al. | Feb 1995 | A |
5421955 | Lau et al. | Jun 1995 | A |
5477864 | Davidson | Dec 1995 | A |
5514154 | Lau et al. | May 1996 | A |
5540820 | Terakado et al. | Jul 1996 | A |
5545210 | Hess et al. | Aug 1996 | A |
5569295 | Lam | Oct 1996 | A |
5593442 | Klein | Jan 1997 | A |
5603721 | Lau et al. | Feb 1997 | A |
5605714 | Dearnaley et al. | Feb 1997 | A |
5607445 | Summers | Mar 1997 | A |
5607463 | Schwartz et al. | Mar 1997 | A |
5609629 | Fearnot et al. | Mar 1997 | A |
5628788 | Pinchuk | May 1997 | A |
5630840 | Mayer | May 1997 | A |
5647858 | Davidson | Jul 1997 | A |
5649951 | Davidson | Jul 1997 | A |
5649977 | Campbell | Jul 1997 | A |
5656036 | Palmaz | Aug 1997 | A |
5683453 | Palmaz | Nov 1997 | A |
5685961 | Pourrezaei et al. | Nov 1997 | A |
5690670 | Davidson | Nov 1997 | A |
5723219 | Kolluri | Mar 1998 | A |
5725573 | Dearnaley et al. | Mar 1998 | A |
5728150 | McDonald et al. | Mar 1998 | A |
5728158 | Lau et al. | Mar 1998 | A |
5733303 | Israel et al. | Mar 1998 | A |
5735896 | Amon et al. | Apr 1998 | A |
5744515 | Clapper | Apr 1998 | A |
5765418 | Rosenberg | Jun 1998 | A |
5772864 | Moller et al. | Jun 1998 | A |
5776161 | Globerman | Jul 1998 | A |
5780807 | Saunders | Jul 1998 | A |
5782908 | Cahalan et al. | Jul 1998 | A |
5782910 | Davidson | Jul 1998 | A |
5788558 | Klein | Aug 1998 | A |
5811151 | Hendriks et al. | Sep 1998 | A |
5824045 | Alt | Oct 1998 | A |
5824049 | Ragheb | Oct 1998 | A |
5824054 | Khosravi et al. | Oct 1998 | A |
5824056 | Rosenberg | Oct 1998 | A |
5840009 | Fischell et al. | Nov 1998 | A |
5843117 | Alt et al. | Dec 1998 | A |
5843120 | Israel et al. | Dec 1998 | A |
5843289 | Lee et al. | Dec 1998 | A |
5849206 | Amon et al. | Dec 1998 | A |
5855600 | Alt | Jan 1999 | A |
5855802 | Acciai et al. | Jan 1999 | A |
5855955 | Claar et al. | Jan 1999 | A |
5858556 | Eckert et al. | Jan 1999 | A |
5866113 | Hendriks et al. | Feb 1999 | A |
5868782 | Frantzen | Feb 1999 | A |
5873904 | Ragheb et al. | Feb 1999 | A |
5876432 | Lau et al. | Mar 1999 | A |
5879370 | Fischell et al. | Mar 1999 | A |
5891507 | Jayaraman | Apr 1999 | A |
5895406 | Gray et al. | Apr 1999 | A |
5897911 | Loeffler | Apr 1999 | A |
5899935 | Ding | May 1999 | A |
5907893 | Zadno-Azizi | Jun 1999 | A |
5913896 | Boyle et al. | Jun 1999 | A |
5919225 | Lau et al. | Jul 1999 | A |
5925063 | Khosravi | Jul 1999 | A |
5932299 | Katoot | Aug 1999 | A |
5938682 | Hojeibane et al. | Aug 1999 | A |
5938697 | Killion et al. | Aug 1999 | A |
5945153 | Dearnaley | Aug 1999 | A |
5951881 | Rogers et al. | Sep 1999 | A |
5955588 | Tsang et al. | Sep 1999 | A |
5962138 | Kolluri et al. | Oct 1999 | A |
5968091 | Pinchuk et al. | Oct 1999 | A |
5972018 | Israel et al. | Oct 1999 | A |
5972027 | Johnson | Oct 1999 | A |
5984905 | Dearnaley et al. | Nov 1999 | A |
5993489 | Lewis et al. | Nov 1999 | A |
6004348 | Banas et al. | Dec 1999 | A |
6007573 | Wallace et al. | Dec 1999 | A |
6013054 | Yan | Jan 2000 | A |
6013855 | McPherson et al. | Jan 2000 | A |
6015429 | Lau et al. | Jan 2000 | A |
6019784 | Hines | Feb 2000 | A |
6022370 | Tower | Feb 2000 | A |
6027526 | Limon et al. | Feb 2000 | A |
6033433 | Ehr et al. | Mar 2000 | A |
6042597 | Kveen et al. | Mar 2000 | A |
6042605 | Martin et al. | Mar 2000 | A |
6056776 | Lau et al. | May 2000 | A |
6059808 | Boussignac | May 2000 | A |
6066167 | Lau et al. | May 2000 | A |
6066168 | Lau et al. | May 2000 | A |
6066169 | McGuinness | May 2000 | A |
6071305 | Brown et al. | Jun 2000 | A |
6086773 | Dufresne et al. | Jul 2000 | A |
6090136 | McDonald et al. | Jul 2000 | A |
6096175 | Roth | Aug 2000 | A |
6103320 | Matsumoto et al. | Aug 2000 | A |
6106642 | DiCarlo et al. | Aug 2000 | A |
6113750 | Shinmura et al. | Sep 2000 | A |
6117535 | Szycher et al. | Sep 2000 | A |
6120536 | Ding et al. | Sep 2000 | A |
6120847 | Yang et al. | Sep 2000 | A |
6124523 | Banas et al. | Sep 2000 | A |
6126793 | Sugiyama et al. | Oct 2000 | A |
6136258 | Wang et al. | Oct 2000 | A |
6190404 | Palmaz et al. | Feb 2001 | B1 |
6202304 | Shatz | Mar 2001 | B1 |
6207536 | Matsumoto et al. | Mar 2001 | B1 |
6245104 | Alt | Jun 2001 | B1 |
6264687 | Tomonto | Jul 2001 | B1 |
6274014 | Matsumoto et al. | Aug 2001 | B1 |
6280467 | Leonhardt | Aug 2001 | B1 |
6287277 | Yan | Sep 2001 | B1 |
6287329 | Duerig et al. | Sep 2001 | B1 |
6287435 | Drewery et al. | Sep 2001 | B1 |
6287628 | Hossainy et al. | Sep 2001 | B1 |
6290720 | Khosravi et al. | Sep 2001 | B1 |
6290721 | Heath | Sep 2001 | B1 |
6293967 | Shanley | Sep 2001 | B1 |
6299604 | Ragheb et al. | Oct 2001 | B1 |
6312463 | Rourke et al. | Nov 2001 | B1 |
6315708 | Salmon et al. | Nov 2001 | B1 |
6315794 | Richter | Nov 2001 | B1 |
6331191 | Chobotov | Dec 2001 | B1 |
6379383 | Palmaz et al. | Apr 2002 | B1 |
6428569 | Brown | Aug 2002 | B1 |
6458152 | Khosravi et al. | Oct 2002 | B1 |
6488701 | Nolting et al. | Dec 2002 | B1 |
6527938 | Bales et al. | Mar 2003 | B2 |
6537310 | Palmaz et al. | Mar 2003 | B1 |
6936066 | Palmaz et al. | Aug 2005 | B2 |
20010000188 | Lenker et al. | Apr 2001 | A1 |
20010001834 | Palmaz et al. | May 2001 | A1 |
20010019847 | Mori et al. | Sep 2001 | A1 |
20010021870 | Edwin et al. | Sep 2001 | A1 |
20010025131 | Edwin et al. | Sep 2001 | A1 |
20010032013 | Marton | Oct 2001 | A1 |
20010037144 | Kim et al. | Nov 2001 | A1 |
20010039449 | Johnson et al. | Nov 2001 | A1 |
20020013616 | Carter et al. | Jan 2002 | A1 |
20020017503 | Banas et al. | Feb 2002 | A1 |
20020046783 | Johnson et al. | Apr 2002 | A1 |
20030028246 | Palmaz et al. | Feb 2003 | A1 |
20030083741 | Woo et al. | May 2003 | A1 |
20040014253 | Gupta et al. | Jan 2004 | A1 |
Number | Date | Country |
---|---|---|
2334223 | Nov 2008 | CA |
19916086 | Oct 1999 | DE |
0747069 | Dec 1996 | EP |
0850607 | Jul 1998 | EP |
0875217 | Nov 1998 | EP |
0850604 | Feb 2003 | EP |
0815806 | Mar 2004 | EP |
0895762 | Feb 2008 | EP |
H61-088135 | Apr 1986 | JP |
H08-500392 | May 1995 | JP |
H08-126704 | May 1996 | JP |
H08-196642 | Aug 1996 | JP |
H10-295823 | Nov 1998 | JP |
H10-295824 | Nov 1998 | JP |
H11-137694 | May 1999 | JP |
WO 97-44692 | Nov 1997 | WO |
WO 98-13537 | Apr 1998 | WO |
WO 98-45506 | Oct 1998 | WO |
WO 99-16385 | Apr 1999 | WO |
WO 99-23977 | May 1999 | WO |
WO 99-36276 | Jul 1999 | WO |
WO 99-39765 | Aug 1999 | WO |
WO 99-62432 | Dec 1999 | WO |
WO 0004204 | Jan 2000 | WO |
WO 0018327 | Apr 2000 | WO |
WO 0054704 | Sep 2000 | WO |
WO 0121851 | Mar 2001 | WO |
WO 0121852 | Mar 2001 | WO |
WO 01-35865 | May 2001 | WO |
WO 0137892 | May 2001 | WO |
WO 0143790 | Jun 2001 | WO |
WO 0149340 | Jul 2001 | WO |
WO 0153559 | Jul 2001 | WO |
WO 0155473 | Aug 2001 | WO |
WO 0174274 | Oct 2001 | WO |
WO 0187371 | Nov 2001 | WO |
WO 03013337 | Feb 2003 | WO |
Entry |
---|
“Adhesion of Bovine Serum Albumin on Coated DLC (Diamond-Like) and Uncoated (SiO2 / TiO2) Sensor Chips”, http://www.phytis.com/stent4.htm, pp. 1-2. |
“Amorphous Carbon and C:N Thin Films”, http://www.glue.umd.edu/˜astan/avs01.htm. |
“Benefits From Diamond-Like Coated Stainless Steel Stents”, http://www.phytis.com/stents0.htm, pp. 1-2. |
“Biocompatibility of Cardiac Cells on Silane-Modified Surfaces”, AVS 46th International Symposium, Paper BI-WeM5 (Oct. 27, 1999). |
“Biofilm—Titanium Chemistry of Adhesion Using X-ray Photoelectron Spectroscopy”, AVS 46th International Symposium, Paper No. BI-FrM8 (Oct. 27, 1999). |
“Biofunctionalization of Surfaces with Peptide Amphilphiles”, AVS 46th International Symposium, Paper No. BI-WeM7 (Oct. 27, 1999). |
L. Buchaillot, et al., “Constitutive Parts of a Shape Memory Alloy Titanium Nickel Thin Film Catheter”, Proceedings of the Second International Conference on Shape Memory and Superelastic Technologies Asilomar Conference Center, Pacific Grove, California, USA, pp. 183-188 (1997). |
J.D. Busch, et al., “Shape Memory Properties in NiTi Sputter-deposited Film”, Journal of Applied Physics, vol. 68, No. 12, pp. 6224-6226 (Dec. 15, 1990). |
K.F. Chiu, et al., “The Control of Film Stress using Ionized Magnetron Sputter Deposition”, Thin Sold Films, pp, 343-344 (1999). |
Curtis, et al., “Reactions of Biological Cells to Nanostructures”, AVS 46th International Symposium, Paper BI-WeM2 (Oct. 27, 1999). |
P.F. Davies, et al., “Endothelial Cell Adhesion in Real Time”, Journal of Clinical Investigation, vol. 91, pp. 2640-2652 (1993). |
P.F. Davies, et al., “Qualitative Studies of Endothelial Cell Adhesion”, Journal of Clinical Investigation, vol. 93, pp. 2031-2038 (1994). |
R. Daw, et al., “Endothelial Cell Organization on Micropatterned Protein Surfaces”, AVS 47th International Symposium, Paper No. BI-WeP21 (Oct. 4, 2000). |
“Directions for Use, DIAMOND AS® Stent”, http://www.phytis.com/direcuse.htm, pp. 1-8. |
W. Ensinger, “The Influence of Ion Irradiation during Film Growth on the Chemical Stability of Film/Substrate Systems”, Surface and Coatings Technology, vol. 80, pp. 35-48 (1996). |
“Expertise Concerning the Implementation of the Phytis DIAMOND AS Stent Performed at the Institute for Experimental Medicine (IEM)”, http://www.phytis.com/stent9.htm, pp. 1. |
“Fabrication of Small-Scale Coils and Bands as Photomasks on Optical Fibers for Generation of In-Fiber Gratings, Electromagnets as Micro-NMR Coils, Microtransformers, and Intra-Vascular Stents”, www.techtransfer.harvard.edu/gci-bin/TALSearch.cgi?full—report=1&case=72, Case No. 1263. |
K.S. Fancey, et al., Abstract: “Relative Importance of Bombardment Energy and Intensity in Ion Plating”, Journal of Vacuum Science & Technology A: Vacuum, Surfaces, and Films, vol. 13, Issue S, pp. 428-435 (Mar. 1995). |
“Flow Cytometric Investigation”, http://www.phytis.com/stent6.htm, pp. 1-3. |
“Focused Ion Beam Non-Fabrication”, http://www.glue.umd.edu/˜astan/avs04.htm. |
K. Gisser, et al., Abstract: “Oriented Nickel-Titanium Shape Memory Alloy Films Prepared by Annealing during Deposition”, Applied Physics Letters, vol. 61, Issue 14, pp. 1632-1634 (Oct. 1992). |
W.J. van der Giessen, et al., “Marked Inflammatory Sequelae to Implantation of Biodegradable and Non-biodegradable Polymers in Porcine Coronary Arteries”, Circulation, vol. 94, No. 7, pp. 1690-1697 (1996). |
F. Goldberg, et al., “The Effects of Ion Irradiation on NiTi Shape Memory Alloy Thin Films”, Proceedings of the Second International Conference on Shape Memory and Superelastic Technologies Asilomar Conference Center, Pacific Grove, California, USA, pp. 177-182 (1997). |
Gordon, et al., “Liquid Sources for Chemical Vapor Deposition of Group 6 Metals and Metal Nitrides” by www.techtransfer.harvard.edu/cgi-bin/TALSearch.cgi?full—report=1&case=3, Case No. 1709. |
H. Hollect, et al., “Multilayer PVD Coatings for Wear Protection”, Surface and Coatings Technology, vol. 76-77, pp. 328-336 (1995). |
J.E. Houston, “The Nanomechanical Properties of Thin Films”, AVS 47th International Symposium, Paper No. TF-TuA1 (Oct. 3, 2000). |
“Invulnerability and Resistance of DLC-Coating”, http://www.phytis.com/stent3.htm, pp. 1-3. |
A. Ishida, et al., “Microstructure of Ti-Rich TiNi Thin Films”, Proceedings of the Second International Conference on Shape Memory and Superelastic Technologies Asilomar Conference Center, Pacific Grove, California, USA, pp. 161-166 (1997). |
A. Peter Jardine, Abstract: “Vacuum conditions for sputtering thin film TiNi”, Journal of Vacuum Science & Technology A: Vacuum, Surfaces, and Films, vol. 13, Issue 3, pp. 1058-1062 (May 1995). |
A.D. Johnson, et al., “Recent Progress in the Application of Thin Film Shape Memory Alloys”, Proceedings of the First International Conference on Shape Memory and Superelastic Technologies Asilomar Conference Center, Pacific Grove, California, USA, pp. 299-310 (1994). |
A.D. Johnson, et al., “Applications of Shape-Memory Alloy Thin Films”, Proceedings of the Second International Conference on Shape Memory and Superelastic Technologies Asilomar Conference Center, Pacific Grove, California, USA, pp. 1-8 (1997). |
Johnson, et al., “Progress in Thin Film Shape Memory Microactuators”, www.sma-mems.com/recent.htm (Overview), pp. 1-5. |
E. Kusano, et al., “Anomalous Plastic and Elastic Behaviors of Sputter-deposited TiNi with 10 or 20 Inserted Thin A1 Layers Evaluated by Nanoindentation”, AVS 47th International Symposium, Paper No. TF-TuA3 (Oct. 3, 2000). |
B.G. Lary M.D., et al., “The Experimental Use of Steel Mesh Tubes for the Replacement of Arterial Segments”, Presented at the Third Scientific Meeting of the North American Chapter of the International Society of Angiology, Atlantic City, N.J., pp. 69-75, Jun. 4, 1955. |
A.E. Lita, et al., “Characterization of Surface Structure in Sputtered AI Films: Correlation to Microstructure Evolution”, Journal of Applied Physics, vol. 85, No. 2, pp. 876-882 (Jan. 15, 1999). |
“Material in Use and Its Biocompatibility”, http://www.phytis.com/stent5.htm, pp. 1-2. |
D. Mattox, “A Concise History of Vacuum Coating Technology, Part 2: 1940 to 1975”, www.svc.org/HistoryofVac2.html, pp. 1-15. |
M. Mrksich, “Model Surfaces for Studying and Controlling the Adhesion of Cells”, AVS 47th International Symposium, Invited Paper No. BI+EL-TuA1 (Oct. 3, 2000). |
“Multicomponent Film Deposition by Target Biasing”, IBM Technical Disclosure Bulletin, pp. 1-2 (Jul. 1980). |
“Multilayer Ceramic/Metallic Coatings by Ion Beam-Assisted, Electron Beam Physical Vapor (EB-PVD) Deposition”, Penn State Applied Research Laboratory, pp. 1-4 (1997). |
“Nanoscale Patterning of Gold for Attachment of Supported Lipid Bilayers” AVS 46th International Symposium, Paper No. BI-FrM10 (Oct. 27, 1999). |
“The New Phytis Stent”, http://www.phytis.com/stent1.htm, pp. 1-2. |
T. Nishikawa, et al., “Tissue Formation of Hepatocytes on Micro-Porous Films of Polylactide”, AVS 47th International Symposium, Paper No. BI+EL-TuA10 (Oct. 3, 2000). |
“Phytis L.D.A. Home Page information”, http://www.phytis.com/content/htm, pp. 1-15. |
Q. Pingshan, et al., “The Effect of HCD Technological Factors on the NiTi SMA Film Thickness”, Proceedings of the Second International Conference on Shape Memory and Superelastic Technologies Asilomar Conference Center, Pacific Grove, California, USA, pp. 173-176 (1997). |
“Plasma Copolymer Surfaces for Cell Culture” AVS 46th International Symposium, Paper No. Paper BI-WeM9 (Oct. 27, 1999). |
“Plasma Co-polymer Surfaces for the Controlled Adsorption of Common Proteins” AVS 46th International Symposium, Paper No. BI-FrM2 (Oct. 29, 1999). |
“Pre-clinical and Clinical Evaluation”, http://www.phytis.com/stent2.htm, pp. 1B2. |
E. Quandt, et al., “Sputter-deposition of TiNi, TiNiPd and TiPd Films Displaying the Two-Way Shape-Memory Effect”, Sensors and Actuators, A 53, pp. 434-439 (1996). |
“Risk Analysis of Stents With a Diamond-Like Coated Surface for Use in Prosthetic Implants”, http://www.phytis.com/risk.htm, pp. 1-6. |
“Sputtering Targets High-Quality Thin Film Materials” by AMETEK Specialty Metal Products online at www.ametek84.com/fd-sputtering.html, pp. 1-3. |
“Stents: Literature”, http://www.phytis.com/liter.htm, pp. 1-8. |
D.S. Sutherland, et al., “Cell Response to Chemically and Topographically Modified Surfaces”, AVS 47th International Symposium, Paper No. BI+EL-TuA3 (Oct. 3, 2000). |
“Thin Film Shape Memory Alloy Microactuators” by TiNi Alloy Company (online). |
J.A. Waker, et al., “Thin-film Processing of TiNi Shape Memory Alloy”, Sensors and Actuators, A21-A23, pp. 243-246 (1990). |
H. Weixin, et al., “The Characteristics of NiTi HCD-Deposited SMA Films”, Proceedings of the Second International Conference on Shape Memory and Superelastic Technologies Asilomar Conference Center, Pacific Grove, California, USA, pp. 167-172 (1997). |
Number | Date | Country | |
---|---|---|---|
20100154197 A1 | Jun 2010 | US |
Number | Date | Country | |
---|---|---|---|
60302797 | Jul 2001 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11157139 | Jun 2005 | US |
Child | 12633716 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10135626 | Apr 2002 | US |
Child | 11157139 | US |